Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Treatment of castrate-resistant prostate cancer.

Logothetis CJ.

J Urol. 2013 Aug;190(2):439-40. doi: 10.1016/j.juro.2013.05.041. Epub 2013 May 21. No abstract available.

PMID:
23707438
2.

Castration-resistant prostate cancer: AUA Guideline.

Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS.

J Urol. 2013 Aug;190(2):429-38. doi: 10.1016/j.juro.2013.05.005. Epub 2013 May 9.

PMID:
23665272
3.

ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.

Sweeney CJ.

Clin Adv Hematol Oncol. 2006 Aug;4(8):588-90. No abstract available.

PMID:
17111557
4.

Metastatic castrate-resistant prostate cancer, dawn of a new age of management.

Nemr EG.

BJU Int. 2013 Mar;111(3):E9-E10. doi: 10.1111/bju.12020_3. No abstract available.

5.

[Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].

Matveev BP, Bukharkin BV.

Vopr Onkol. 1998;44(5):537-40. Review. Russian.

PMID:
9884710
6.

[Treatment of carcinoma of the prostate with analogs of LHRH].

Rubio Herrera MA, Calle Fernández JR.

Rev Clin Esp. 1986 Nov;179(8):407-11. Spanish. No abstract available.

PMID:
2951782
7.

[Optimal treatment for elderly high-risk prostate cancer patients].

Soga N, Sugimura Y.

Gan To Kagaku Ryoho. 2007 Mar;34(3):387-92. Review. Japanese.

PMID:
17353629
8.

[A case of prostate cancer treated with combined androgen-blockade].

Kurita M, Kato Y, Tamura Y, Suzuki K, Yamanaka H.

Gan To Kagaku Ryoho. 2000 Feb;27(2):307-10. Japanese.

PMID:
10700907
9.

New therapies for castration-resistant prostate cancer: efficacy and safety.

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.

Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4. Review.

PMID:
21592649
10.

Editorial: the coming revolution in the treatment of prostate cancer patients.

Petrylak DP, de Wit R.

Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):1-3. No abstract available.

PMID:
12198631
11.

Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents.

Schally AV, Redding TW, Paz-Bouza JI, Comaru-Schally AM, Mathe G.

Prog Clin Biol Res. 1987;243A:173-97. Review. No abstract available.

PMID:
2889215
12.

Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer.

Denis L, Murphy GP.

Cancer. 1993 Dec 15;72(12 Suppl):3888-95. No abstract available.

13.

Defining new standards of care for men with prostate cancer.

Scher HI.

Lancet. 2016 Mar 19;387(10024):1135-7. doi: 10.1016/S0140-6736(15)01235-0. No abstract available.

14.

CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers.

Teo MY, Scher HI.

Nat Rev Clin Oncol. 2015 Dec;12(12):687-8. doi: 10.1038/nrclinonc.2015.192. Epub 2015 Nov 10. No abstract available.

PMID:
26552950
15.

[Palliative systemic therapy of castration-resistant prostate cancer: current developments].

Finter F, Rinnab L, Gust K, Küfer R.

Urologe A. 2009 Nov;48(11):1295-301. doi: 10.1007/s00120-009-2111-4. Review. German.

PMID:
19847385
16.

Chemotherapy in patients with castration-resistant prostate cancer.

Meulenbeld HJ, Hamberg P, de Wit R.

Eur J Cancer. 2009 Sep;45 Suppl 1:161-71. doi: 10.1016/S0959-8049(09)70029-2. Review. No abstract available.

PMID:
19775615
19.

[Chemotherapy of the hormone-refractory prostate cancer].

Heine K, Wolff JM.

Aktuelle Urol. 2004 Jun;35(3):209-14. Review. German.

PMID:
15258854
20.

[New perspectives in the drug therapy of hormone-resistant prostate cancer].

Vorob'ev NA, Nosov AK, Vorob'ev AV, Moiseenko VM.

Vopr Onkol. 2010;56(6):645-53. Review. Russian. No abstract available.

PMID:
21395118

Supplemental Content

Support Center